Kodiak Sciences Inc. (KOD) experienced a significant pre-market surge of 5.56% on Friday.
The sharp increase appears to be driven by bullish analyst actions, as multiple firms raised their price targets for the biopharmaceutical company. H.C. Wainwright increased its target to $58 from $38, while Jefferies raised its target to $56 from $39. These substantial upward revisions signal improved analyst confidence and likely prompted investor optimism in the pre-market session.